Mesenchymal Stromal Cell-Based Cell Therapy: Recent Advances and Expectations
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1100
Special Issue Editors
Interests: angiogenesis; cancer biology; spheroids; mesenchymal stromal cells; cancer associated fibroblasts; perinatal derivatives
Special Issues, Collections and Topics in MDPI journals
Interests: immunomodulation; mesenchymal stromal cells; cancer biology; regenerative medicine; immunology; perinatal derivatives; secretoma; extracellular vesicles
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mesenchymal stromal cells (MSCs) can be derived from various human tissues and organs. These cells exhibit a multipotent differentiation capacity in vitro. Although this characteristic has made them appealing for regenerative medicine applications due to their potential to regenerate damaged tissue, it has been observed over the years that the true therapeutic effect of these cells is associated with their paracrine action, particularly their ability to modulate the surrounding microenvironment, thereby promoting tissue homeostasis restoration. Numerous in vitro and in vivo studies have demonstrated that the secretome of MSCs, comprising the factors produced and released by these cells, including proteins, lipids, extracellular vesicles, and other factors, plays a pivotal role not only in the context of regenerative medicine but also in the tumor microenvironment. Through their immunomodulatory action, MSCs can contribute to the tumor's immune evasion mechanism.
Indeed, various components released by MSCs, particularly extracellular vesicles, among the factors responsible for their paracrine action, play a significant role in modulating the tumor microenvironment and influencing tumor development. Recent studies have specifically highlighted the critical involvement of mesenchymal stromal cell-derived exosomes (MSC-derived exosomes) in cancer resistance to chemotherapy agents, targeted therapy drugs, radiotherapy, and immunotherapy.
We invite original research and review articles that can contribute to the advancement of knowledge and discussion on two aspects of MSC paracrine activity:
- The ability to exert a pro-regenerative action;
- The capacity to play a significant role in the tumor microenvironment or potentially act therapeutically in the field of oncology.
Dr. Paola Chiodelli
Dr. Andrea Papait
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- exosome
- mesenchymal stem cell
- therapy resistance
- regenerative medicine
